ANTIMICROBIAL AGENT

Abstract

A compound according to formula (I) or formula (Ia), and a composition comprising the compound for use as an antimicrobial: wherein, X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently selected from: N, O, S; Y.sub.1 and Y.sub.2 are each independently selected from: N, O, S, C(R.sub.a); M.sub.1 and M.sub.2 are each a metal centre; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ra are each independently selected from: hydrogen, alkyl, alkenyl, aryl, halogen, haloalkyl, haloalkenyl, haloaryl, hydroxy, alkoxy, carboxylic acid, amino, amido, nitro or combination thereof; A.sub.1, A.sub.2, A.sub.3 and A.sub.4 are each bidentate ligands; and rings D.sub.1 and D.sub.2 are each independently comprise one or more heteroatoms selected from N, O, S, C(R.sub.a); wherein said compound is for use as an antimicrobial.

Claims

1. A compound according to formula (I) or formula (Ia): ##STR00011## wherein, X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently selected from: N, O, S; Y.sub.1 and Y.sub.2 are each independently selected from: N, O, S, C(R.sub.a); M.sub.1 and M.sub.2 are each a metal centre; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.a are each independently selected from: hydrogen, alkyl, alkenyl, aryl, halogen, haloalkyl, haloalkenyl, haloaryl, hydroxy, alkoxy, carboxylic acid, amino, amido, nitro or combination thereof; A.sub.1, A.sub.2, A.sub.3 and A.sub.4 are each bidentate ligands; and rings D.sub.1 and D.sub.2 are each independently comprise one or more heteroatoms selected from N, O, S, C(R.sub.a); wherein said compound is for use as an antimicrobial.

2. A compound according to claim 1, wherein the compound is for use as an antibiotic.

3. A compound according to claim 2, wherein the compound is for use against gram-negative bacteria.

4. A compound according to claim 1, wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each N.

5. A compound according to claim 1, wherein Y.sub.1 and Y.sub.2 are each N.

6. A compound according to claim 1, wherein M.sub.1 and M.sub.2 are each ruthenium.

7. A compound according to claim 1, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.a are each independently selected from: hydrogen, alkyl and aryl.

8. A compound according to claim 1, wherein the bidentate ligand is a compound according to formula (III): ##STR00012## wherein, Z.sub.1 and Z.sub.2 are each independently selected from: N, O, S; and R.sub.5, R.sub.6, and R.sub.7 are each independently selected from: hydrogen, alkyl, alkenyl, aryl, halogen, haloalkyl, haloalkenyl, haloaryl, hydroxy, alkoxy, carboxylic acid, amino, amido, nitro or combination thereof.

9. A compound according to claim 8, wherein R.sub.5, R.sub.6, and R.sub.7 are each independently selected from: hydrogen, alkyl and aryl.

10. A compound according to claim 8, wherein Z.sub.1 and Z.sub.2 are each N.

11. A compound according to claim 1, wherein A.sub.1, A.sub.2, A.sub.3 and A.sub.4 are each bidentate ligands independently selected from (1) to (7): ##STR00013## or combination thereof.

12. A compound according to formula (IV) or (IVa): ##STR00014## wherein R.sub.8, R.sub.8′, R.sub.8″, R.sub.8′″, R.sub.9, R.sub.9′, R.sub.9″, R.sub.9′″, R.sub.10, R.sub.10′, R.sub.10″, R.sub.10′″, R.sub.11, R.sub.11′, R.sub.11″, R.sub.11′″, R.sub.12, R.sub.12′, R.sub.12″, R.sub.12′″, R.sub.13, R.sub.13′, R.sub.13″ and R.sub.13′″ are each independently selected from: hydrogen, alkyl, alkoxy, alkenyl and aryl; with the proviso that at least one of R.sub.8, R.sub.8′, R.sub.8″, R.sub.8′″, R.sub.9, R.sub.9′, R.sub.9″, R.sub.9′″, R.sub.10, R.sub.10′, R.sub.10″, R.sub.10′″, R.sub.11, R.sub.11′, R.sub.11″, R.sub.11′″, R.sub.12, R.sub.12′, R.sub.12″, R.sub.12′″, R.sub.13, R.sub.13′, R.sub.13″ and R.sub.13′″ is selected from: alkyl, alkoxy, alkenyl and aryl; and wherein R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20 and R.sub.21 are each independently selected from: hydrogen, alkyl, alkenyl, aryl, halogen, hydroxy, alkoxy or combinations thereof.

13. A compound according to claim 12, wherein: R.sub.8, R.sub.8′, R.sub.8″ and R.sub.8′″ are identical; R.sub.9, R.sub.9′, R.sub.9″ and R.sub.9′″ are identical; R.sub.10, R.sub.10′, R.sub.10″ and R.sub.10′″ are identical; R.sub.11, R.sub.11′, R.sub.11″ and R.sub.11′″ are identical; R.sub.12, R.sub.12′, R.sub.12″ and R.sub.12′″ are identical; and R.sub.13, R.sub.13′, R.sub.13″ and R.sub.13′″ are identical.

14. A compound according to claim 12, having a structure according to formula (V) or formula (Va): ##STR00015## or pharmaceutically acceptable salt thereof.

15. A composition comprising the compound according to claim 1.

16. A composition according to claim 15, for use as an antimicrobial.

Description

DESCRIPTION OF FIGURES

[0055] FIG. 1A shows the uptake and cell death effects of 4.sup.4+. Complex 4.sup.4+ induces dose-dependent killing of E. coli MG1655 (top) and EC958 (bottom) planktonic cultures in vitro. The complex was added at various concentrations below and exceeding the MIC, 1.2 μM (A) or 1.6 μM (B), of 4.sup.4+ in GDMM. Killing was determined by monitoring the number of colony forming units (CFU) per mL at time intervals up to 6 h post treatment. Error bars represent three independent biological repeats ±standard deviation (SD).

[0056] FIG. 1B shows the uptake of cell death effects of 4.sup.4+. ICP-AES data for the uptake of ruthenium by E. coli EC958 in the absence (left) and presence (right) of glucose after exposure to 4.sup.4+. Ru (top line) and Fe (bottom line) levels per cell are expressed as metal (g) per cell. Fe levels were calculated as a control. Conditions: concentration of 4.sup.4+=0.8 μM. Cells were washed with 0.5% (v/v) nitric acid to remove unbound complex. Error bars represent three independent biological repeats ±SD.

[0057] FIG. 2 shows the localization of 4.sup.4+ in E. coli EC958 cells visualized through Laser Scanning Confocal Microscopy (LSCM) and Stimulated Emission Depletion (STED) nanoscopy at 5, 20, 60, and 120 minutes. Top row: cells imaged using the emission of 4.sup.4+ on excitation at 470 nm with a White Light Laser and a 470 nm notch filter. Middle row: cells imaged with the same excitation and emissions settings; STED effect was obtained employing a 775 nm depletion laser, and a 780 nm vortex phase plate. Both deconvoluted diffraction-limited images (d-LSCM) and super resolution (d-STED) images were processed using commercial Huygens software (SVI). The arrowheads highlight regions where 4.sup.4+ preferentially accumulates. Bottom row: normalised emission intensity profile along the solid white lines drawn on top of selected region of cells shown in the middle row; solid black lines represent the d-LSCM, solid red lines represent d-STED. Conditions: after treatment with 0.8 μM 4.sup.4+, cells were washed with nitric acid before fixing with paraformaldehyde (16%).

[0058] FIG. 3 displays representative images showing section planes of full-volume deconvoluted diffraction-limited cells and super-resolution images (d-LSCM and d-3D STED). Normalised emission intensity profile of the solid white lines drawn on top of selected region of cells are plotted. Solid black lines represent the d-LSCM, solid red lines represent d-3D STED. Zoomed-in areas of the dashed white squared drawn for each time point are shown adjacent to the images, as well as the orthogonal representation of every axis (XY, XZ, and YZ), where the increased resolution and better localisation of 4.sup.4+ is shown in green. The 10 and 20 minutes time points show accumulation at specific locations within the cell membrane; by the 60 minutes time point the compound localises at sections of the cell poles as can be seen in the zoomed in regions (a, b, c, d). Conditions used are identical to those employed in FIG. 2.

[0059] FIG. 4A shows evidence of membrane damage in E. coli EC958. Co-localization of 4.sup.4+ and NHS-ester 405 visualized through SIM at 5 minutes (left), and 60 minutes (right). (i) Cells treated with 0.8 μM 4.sup.4+ and fixed with paraformaldehyde (16%). After fixation cells were treated with 2.5 μg/mL of NHS-ester 405. Top panel: emission of 4.sup.4+ (A568 filter) middle panel: NHS-ester 405 emission at 405 nm (DAPI filter Bottom panel: merged images. (ii). Staining with NHS-ester in the absence of 4.sup.4+.

[0060] FIG. 4B shows 4.sup.4+ induced ATP release from EC958 cells, extracellular [ATP] (nM) quantified with recombinant luciferase and D-luciferin with ATP released measured on a luminometer for samples exposed to 0 (control), 0.8 and 1.6 μM (MIC) of 4.sup.4+ over a period of two hours. A three-star significant difference is observed between 0 and 1 MIC, P value=0.0006. Error bars represent three biological repeats ±SD. ATP positive contro—polymyxin 4 μg/mL (inset). IC.sub.50/MIC comparison for HEK293 cells and three bacteria strains.

[0061] FIG. 4C shows IC.sub.50/MIC comparison for HEK293 cells and three bacteria strains.

[0062] FIG. 4D shows a Galleria mellonella toxicity screen Kaplan-Meier survival curves, cells treated with 0-80 mg/kg of compound 4.sup.4+, incubated at 37.5° C. for 120 hours—water control (black), compound 4.sup.4+ (red).

[0063] FIG. 5A shows UV-Vis absorption spectrum showing the change in molar extinction coefficient upon increasing concentration of [{Ru(3,4,7,8-tetramethyl-1,10-phenanthroline)2}2(tpphz)] in MeCN (conducted on a Cary 300 UV/Vis spectrophotometer at 27.5° C.).

[0064] FIG. 5B shows UV-Vis absorption spectrum showing the change in molar extinction coefficient upon increasing concentration of [{Ru(3,4,7,8-tetramethyl-1,10-phenanthroline)2}2(tpphz)] in water (conducted on a Cary 300 UV/Vis spectrophotometer at 27.5° C.).

[0065] FIG. 6A shows emission spectra at increasing concentration of [{Ru(3,4,7,8-tetramethyl-1,10-phenanthroline).sub.2}.sub.2(tpphz)] between 550-800 nm in MeCN. Conducted on a Fluoromax 3 fluorimeter at 27.5° C.

[0066] FIG. 6B shows emission spectra at increasing concentration of [{Ru(3,4,7,8-tetramethyl-1,10-phenanthroline).sub.2}.sub.2(tpphz)] between 550-800 nm in water. Conducted on a Fluoromax 3 fluorimeter at 27.5° C.

[0067] FIG. 7 shows a comparison of the Log P values determined and the activity (MIC) of each complex against the pathogenic E. coli strain EC958, to show the increase in activity with relative increase in lipophilicity. Log P data was collected using the shake flask procedure. “Phen” is phenanthroline, “DMP” is dimethyl phenanthroline, “TMP” is tetramethyl phenanthroline and “DIP” is diphenyl phenanthroline.

[0068] FIG. 8 shows CFU/mL counts for the accumulation experiment of 4.sup.4+ by EC958, to ensure that the number of bacteria in the solution maintained constant between each time point.

[0069] FIG. 9 shows the difference in Ru content per cell (g) at each time point (+) with glucose and (−) without glucose for 4.sup.4+. Showing significant differences in accumulation of ruthenium in the (+) with glucose sample at 10 and 20 minutes. Ruthenium content per cell determined via ICP-AES.

[0070] FIG. 10A shows DNA binding titration using increasing concentrations of CT-DNA and 4.sup.4+ in Tris buffer at 27° C., conducted on a Fluoromax 3.

[0071] FIG. 10B shows a scatchard plot and McGhee Von Hippel fit, to find the binding constant of 4.sup.4+.

[0072] FIGS. 11A and 11B show the detection of membrane potential in E. coli EC958 cells. The percentage population of cells (%) containing red/red+green/green fluorescence are given. Cells were incubated with 30 μM of Di-OC2(3) for 30 minutes in the presence or absence of 1.6 μM of 4.sup.4+.

[0073] FIGS. 12A and 12B show the analysis of the flow cytometry data using red and green fluorescence parameters. The red-versus-green fluorescence dot plots were collected with log amplification.

[0074] FIG. 13 shows Acetinobacter baumannii (AB184) stained with 4.sup.4+ at MIC concentration at 10 minutes (left) and 60 minutes (right), corresponding to imaging of the outer membrane (10 minutes) and the inner membrane (60 minutes). Cells fixed with PFA (4%) and washed with PBS. Cells were imaged on a structured illumination microscope using the 488 nm laser and an A568 filter.

[0075] FIG. 14 shows the ruthenium haemolymph content (μg/mL) for Galleria mellonella injected with 20 mg/kg (blue) and 80 mg/kg (red). Galleria were injected with 10 μL 4.sup.4+/water into their left pro-leg, incubated at 37.5° C. for 120 hours. At each time interval, the Galleria were scored: live/dead, activity and melanisation. Ru content was determined via ICP-AES.

[0076] FIG. 15 shows Galleria mellonella (CFU 10.sup.5—left and 10.sup.6—right) toxicity screen Kaplan-Meier survival curves, cells treated with 0-80 mg/kg of 4.sup.4+, incubated at 37.5° C. for 120 hours—water control (orange), bacteria (green) and 4.sup.4+ (purple). Co-injected larvae were injected with bacteria in their right pro-leg then 4.sup.4+30 minutes later in their left pro-leg.

[0077] FIG. 16A shows the Bacteria CFU counts from extracted larvae hemolymph (Galleria mellonella), observed for 120 hours in the presence of 40 mg/kg and 80 mg/kg 4.sup.4+, with extractions taken at 24 and 120 hours. Initial bacterial count 10.sup.5 (left) and 10.sup.6 (right). Larvae were incubated at 37.5° C.

[0078] FIG. 16B shows photographs of the agar plates used to determine the plots of FIG. 16A and show a 0 mg/kg, 40 mg/kg and 80 mg/kg dosing of 4.sup.4+ after 24 hours. Complete clearance was observed in 96 hours at 40 and 80 mg/kg doses, with a single dose. The black marks are not bacteria colonies, but melanised hemolymph.

[0079] FIG. 17 shows the localization of 4.sup.4+ in A. baumannii AB184 cells within the larvae's hemolymph using confocal microscopy. Top Row: cells imaged using the emission of 4.sup.4+ on excitation at 450 nm using A568 filter. Middle row: phase contrast. Bottom Row: combined image. Extracted hemolymph cells were washed with nitric acid before fixing with paraformaldehyde (16%).

[0080] FIGS. 18 A-C are images through cleared Galleria mellonella larvae. The luminescence of complex 4.sup.4+ in stained A. baumannii AB184 was determined (head A, tail B). Hemocyte containing regions I and II of the bacterial cells are highlighted. A. baumannii were stained with 1.2 μM 4.sup.4+ for 30-minutes then fixed with PFA (4%). Larvae were injected with cells and incubated for 30-minutes, larvae anaethetised with diethyl ether were incubated in PFA (4%) for 30 minutes, prior to clearing with the CUBIC protocol. Images were taken on a Nikon Confocal Microscope using the 488 nm laser and red emission filter. Images were processed using Image J.

[0081] FIG. 19 provides a series of images of cleared Galleria mellonella larvae infected with A. baumannii, AB184, stained with NHS-ester 488-0.5 mg/mL (A) or complex 4.sup.4+-1.2 μM (B). Sections of the cells are identified (i) and expanded (AII, AIII, BII) to show A. baumannii within the hemocyte cells. 3D surface plots (AIV, BIII) are given to show peak emission intensity. Conditions are the same as FIG. 18 Images were taken on a Fluorescence Stereomicroscope: 490 nm ex/520 nm em (NHS-ester 488), 565 nm ex/640 nm. Images were processed using Image J.

[0082] FIG. 20 shows biofilm formation of E. coli ST131, EC958, when subjected to different concentrations of 4.sup.4+. N≥3±SEM. Biofilm formed over 19 hours of incubation at 37° C. in 24-well plates. ST131 shows biofilm formation in no Ruthenium and 0.156 μM (10% of MIC),

[0083] FIG. 21 shows biofilm CFU/mL produced by E. coli ST131 when existing biofilms were subjected to 15.6 μM, 78 μM and 156 μM of 4.sup.4+. N≥3±SEM. four day biofilm grown on filter membrane at 37° C. with MHA changed daily. Compound pipetted directly onto biofilm on day four, incubated for 24 hours. CFU/ml calculated using Miles and Mirsa method. One-way ANOVA performed with Turkey's multiple comparison tests.

[0084] FIGS. 22A and 22B show 4.sup.2+ in EC958 showing helical DNA binding and mono-TMP in SH1000 again showing DNA binding.

[0085] FIG. 23 shows the uptake of cell death effects of 4.sup.2+. ICP-AES data for the uptake of ruthenium by E. coli EC958 in the absence (a) and presence (b) of glucose after exposure to 4.sup.2+. Ru (top line) and Fe (bottom line) levels per cell are expressed as metal (g) per cell. Fe levels were calculated as a control. Conditions: concentration of 4.sup.2+=0.8 μM. Cells were washed with 0.5% (v/v) nitric acid to remove unbound complex. Error bars represent three independent biological repeats ±SD.

[0086] FIG. 24 shows the difference in Ru content per cell (g) at each time point (+) with glucose and (−) without glucose for 4.sup.2+. Showing significant differences in accumulation of ruthenium in the (+) with glucose sample at 10 minutes. Ruthenium content per cell determined via ICP-AES.

[0087] FIG. 25 shows the relative rates of uptake of Ru for 4.sup.2+ and 4.sup.4+ based on the results of FIGS. 1B and 23.

[0088] FIGS. 26 A-C show the localization of 4.sup.2+ in E. coli EC958 cells visualized through Laser Scanning Confocal Microscopy (LSCM) and Stimulated Emission Depletion (STED) nanoscopy at 60 minutes, 120 minutes and 24 hours. The cells were imaged using the emission of 4.sup.2+ on excitation at 470 nm with a White Light Laser and a 470 nm notch filter, deconvoluted diffraction-limited images (d-LSCM) and super resolution (d-STED) images were processed using commercial Huygens software (SVI). Conditions: after treatment with 0.8 μM 4.sup.2+, cells were washed with nitric acid before fixing with paraformaldehyde (16%).

[0089] FIG. 27 shows the results of a DNA co-staining experiment. S. aureus stained with 4.sup.2+ (top and CI), S. aureus stained with the DNA stain DAPI (CII), overlay image (CIII), overlay 3D surface plot (CIV). The image shows a direct overlay of DAPI and Mono-TMP to calculate a Pearson's colocalisation constant of >0.9.

[0090] FIG. 28 shows the results of an Ames mutagenic assay for E. coli in the presence of 4.sup.2+. Percentage mutagenesis was measured by treating E. coli (25% overnight culture, 75% media) cells with 4.sup.2+ at 0 (natural mutagenesis control), 0.5, 1.0 and 2.0×. Bromocresol purple indicator was added, and the percentage colour change from purple to yellow measured after incubation for 48 hours. A positive control with cells irradiated with UV-light was added for comparison.

[0091] FIG. 29 shows TEM images of E. coli in the presence of 4.sup.2+.

[0092] FIG. 30 shows 4.sup.2+ induced ATP release from E. coli EC958 cells, extracellular [ATP] (nM) quantified with polymyxin measured on a luminometer for samples exposed to 0 (control), 0.5 MIC and 1.0 MIC of 4.sup.2+ over a period of four hours. Error bars represent three biological repeats ±SD. Polymyxin 4 μg/mL.

[0093] FIG. 31 shows a Galleria mellonella toxicity screen Kaplan-Meier survival curves, cells treated with 0-80 mg/kg of 4.sup.2+, incubated at 37.5° C. for 120 hours—water control (black), compound (red).

[0094] FIG. 32 shows A. baumannii AB184 toxicity screen Kaplan-Meier survival curves (initial bacterial count 10.sup.4—left and 10.sup.5—right), cells treated with 40 or 80 mg/kg of 4.sup.2+, incubated at 37.5° C. for 120 hours—water control (red), compound (green).

[0095] FIG. 33A shows the Bacteria CFU counts from extracted larvae hemolymph (A. baumannii AB184), observed for 120 hours in the presence of 40 mg/kg and 80 mg/kg 4.sup.2+. Initial bacterial count 10.sup.4 (left) and 10.sup.5 (right).

[0096] FIG. 33B shows photographs of the agar plates used to determine the plots of FIG. 33A with regard to the 80 mg/kg dosing of 4.sup.2+. The black marks are not bacteria colonies, but melanised hemolymph.

[0097] The invention will now be described with respect to specific examples. These examples are not to be construed as limiting and are provided to improve understanding of the invention.

EXAMPLES

Synthesis of Dinuclear Complexes

[0098] Complexes 1.sup.4+ and 2.sup.4+ (see scheme 1) were synthesized using the procedures outlined below.

##STR00009##

1,10-phenanthroline-5,6-dione (Compound 1.SUP.4+.)

[0099] 1,10-phenanthroline (18.02 g, 100 mmol) was dissolved into 60% H.sub.2SO.sub.4 (125 mL). With constant stirring potassium bromate (66.81 g, 400.1 mmol) was added slowly to prevent the reaction becoming too vigorous. Reaction liberated brown fumes of bromine gas. Once all potassium bromate was added the reaction mixture was left to cool to room temperature. The mixture was further cooled by adding crushed ice (100 g) and placing in an ice bath. The solution was neutralised to pH 5-6 by dropwise addition of NaOH (20M), during neutralisation the mixture becomes hot this must be conducted in an ice bath to keep it cool. The yellow precipitate was filtered on a sinter and washed with water (1 L) and diethyl ether (100 mL). The product was dried in vacuo. The crude product was purified via recrystallisation in water/methanol (1:50) the bright yellow crystals were collected via vacuum filtration. Mass=16.04 g (76.31 mmol, 76.3%) yellow solid. .sup.1HNMR (CDCl.sub.3) δ (splitting integration); 7.61 (dd, 2H), 8.52 (dd, 2H), 9.13 (dd, 2H). MS; m/z: 210.1 (100) [M+].

Tetrapyrido[3,2-a:2′,3′-c:3′-c:3″,2″-h:2′″,3′″-j]phenazine (TPPHZ)

[0100] Ammonium acetate (15 g, 194.6 mmol), dip (2.90 g, 13.8 mmol) and sodium dithionite (300 mg, 1.72 mmol) were boiled under reflux for 2 hours at 180° C. under nitrogen. The reaction mixture was stirred occasionally. Once the reaction was complete the mixture was left to cool to room temperature, then distilled water (20 mL) was added.

[0101] The yellow precipitate formed was collected, filtered under vacuum and washed with water, methanol and acetone (3×20 mL). The resulting crude product was triturated in refluxing ethanol (100 mL) to remove impurities, filtered whilst hot and dried in vacuo. Mass=(0.92 g, 2.39 mmol, 34.6%) yellow solid. The product was sparingly soluble in most solvents. .sup.1HNMR (CDCl.sub.3) δ (splitting integration) 7.94 (dd, 4H), 9.41 (dd, 4H), 9.83 (dd, 4H). .sup.1HNMR (d-TFA) δ (splitting integration) 8.62 (dd, 4H), 9.56 (dd, 4H), 10.52 (dd, 4H). MS; m/z (42.6%): 385.1 (100) [M+].

Ru(N—N).SUB.2.Cl.SUB.2

[0102] Four compounds were synthesised by the following method, where N—N represents the substituted phenanthroline ancillary ligand. RuCl.sub.3.3H.sub.2O, N—N and LiCl were heated in DMF for 8 hours under reflux. The reaction mixture was cooled to room temperature and acetone added. This was stored at 4° C. for 16 hours. The dark purple precipitate was washed with water and ethanol and dried in vacuo.

Ru(1,10-phenanthroline).SUB.2.Cl.SUB.2

[0103] RuCl.sub.3.3H.sub.2O (1.56 g, 6 mmol), LiCl (1.55 g, 36.9 mmol), phen (2.5 g, 13.9 mmol), DMF (20 mL) and acetone (100 mL). Mass=2.41 g (4.59 mmol, 66.1% yield). ES-MS m/z (%): 497 (70) [M−Cl].sup.+, 525 (100) [M−Cl].sup.++CO.

[{Ru(N—N).SUB.2.}.SUB.2.(tpphz)][PF.SUB.6.].SUB.4

[0104] The four compounds were synthesized by the following general procedure. [Ru(N—N).sub.2Cl.sub.2] and (tpphz) were added to a 1:1 solution of ethanol and water. The solution was heated at reflux for 12 hours under nitrogen. After completion the reaction mixture was cooled to room temperature and stored at 4° C. for 16 hours. The red solution was filtered and the ethanol removed by rotary evaporation. A saturating amount of NH.sub.4PF.sub.6 was added; this caused the formation of a dark red precipitate. The precipitate was collected by filtration, washed with water and recrystallized in acetonitrile by addition of diethyl ether. The product was dried in vacuo and purified on an alumina column, using the following solvent system: was 95% MeCN, 3% dH.sub.2O and 2% KNO.sub.3.

[{Ru(1,10-phenanthroline).SUB.2.}.SUB.2.(tpphz)][PF.SUB.6.].SUB.4

[0105] Tpphz (0.263 g, 0.68 mmol), [Ru(phen).sub.2Cl.sub.2] (1 g, 1.89 mmol) and ethanol/water (50 mL). Mass=1.1 g (0.58 mmol, 85.6% yield). .sup.1H NMR (MeCN-d.sup.6) δ (splitting integration): 7.71 (m, 8H), 7.94 (dd, 4H), 8.09 (d, 4H), 8.29 (dd, 8H), 8.33 (s, 8H), 8.69 (dd, 8H), 10.01 (dd, 4H). ES-MS; m/z (%): 799 (10) [M−2PF.sub.6].sup.2+, 484 (15) [M−3PF.sub.6].sup.3+, 321 (50) [M−4PF.sub.6].sup.4+, Accurate mass analysis: C.sub.72H.sub.28N.sub.14[.sup.102Ru].sub.2.sup.4+ Calculated 321.1110. Found 321.1112.

[0106] Complexes 3.sup.4+ and 4.sup.4+ were synthesised using similar methods, employing the relevant methylated bidentate ligands. Both 3.sup.4+ and 4.sup.4+ display the expected intense Ru.sup.II.fwdarw.tpphz based .sup.3MLCT emission in MeCN centred at 670 nm and 700 nm respectively (FIGS. 5 and 6). The biological properties of each of these four complexes were studied using their chloride salts, which were obtained by anion metathesis.

Properties of Dinuclear Complexes

[0107] The balance of lipophilicity and hydrophilicity is believed to be important for live-cell uptake of bioactive substrates. The Log P for all four complexes were determined through octanol-water partition using the shake flask procedure. The results were as follows: 1.sup.4+=1.77, 2.sup.4+=1.03, 3.sup.4+=1.38 and 4.sup.4+=1.13. These data reveal that 2.sup.4+ is the most lipophilic complex. Further, the relative lipophilicity appears to increase with the number of methyl groups attached to the ancillary ligands of these complexes.

[0108] The bioactivity of these compounds was investigated with respect to the wild type K12-derivative MG1655 and uropathogenic multidrug resistant EC958 ST131 strains of E. coli. Another gram-positive bacteria, ESKAPE bacteria—the pathogenic gastrointestinal strain of Enterococcus faecalis, V583 (ATCC700802)—which is a major opportunistic pathogen (and a leading cause of urinary tract infections) was also tested with respect to the compounds. The minimum inhibitory concentration, MIC, of the four complexes was obtained in both glucose defined minimal media (GDMM) and nutrient rich Mueller-Hinton-II (MH-II) (FIG. 7). As demonstrated by the data in Table 1, all four complexes show higher activity in GDMM.

TABLE-US-00001 TABLE 1 MIC (μM) and MBC (μM) results for E. coli wild type (MG1655) and pathogenic (EC958) strains and E. faecalis pathogenic (V583) strain in GDMM and MH-II. Complex MG1655 EC958 V583 MG1655 EC958 V583 GDMM MIC Values MH-II MIC Values 1.sup.4+ 2.3 2.8 21.3 12.9 14.7 64 2.sup.4+ 7.8 10.4 64 139.9 145.1 64 3.sup.4+ 2.5 2.5 8 6.8 6.8 42.7 4.sup.4+ 1.2 1.6 0.5 5.6 5.6 3.3 ampicillin 3.3 — 1 5.7 — 0.5 GDMM MBC Values MH-II MBC Values 1.sup.4+ 11 4.3 53.3 11 4.6 53.3 2.sup.4+ 15.5 25.9 85.3 15.5 25.9 85.3 3.sup.4+ 20.3 5.1 53.3 20.3 5.1 53.3 4.sup.4+ 2.4 2.4 4 2.4 2.4 4 ampicillin 11.4 — 6.3 11.4 — 6.3

[0109] Although the most lipophilic compound, 2.sup.4+, shows the least activity—most likely due to its lower solubility in aqueous media—the lipophilic series shows an increase in lipophilicity and a concomitant increase in activity, with 4.sup.4+ having the highest activity against all three strains of bacteria. Notably, 1.sup.4+, 3.sup.4+ and 4.sup.4+ showed appreciable activity against β-lactam-resistant strain of E. coli, and the vancomycin resistant strain of E. faecalis; complex 4.sup.4+ even displays higher activity than ampicillin against the wild type strain of E. coli. Estimates of minimum bactericidal concentration, MBC, for 1.sup.4+-4.sup.4+ were also obtained and summarized in Table 1. These data show that, as for the MIC data, an increase in MBC values between GDMM and MH-II is observed. Again, 4.sup.4+ is the most active, and in GDMM its MBC values were lower than ampicillin, indicating that, for all strains of bacteria, it is more active than the conventional antibiotic. Furthermore, as MBC values against all three strains exceed the MICs by at least 4-fold, all compounds function as bacteriostatic antimicrobial agents.

[0110] Having established that complex 4.sup.4+ had the most promising bactericidal properties, time-kill kinetics assays were carried out for both E. coli strains during 6 hours of exposure to increasing concentrations of the complex in minimal media at 37° C. (see FIGS. 1A and 8). At concentrations lower than the MIC there was a gradual increase in colony forming units (CFU), as the bacteria continued to grow. In both strains, it is evident that, at concentrations of MIC and above, the compound halts the bacterial proliferation and reduces the number of viable bacterial cells. For EC958 at the highest exposure to 4.sup.4+ no colonies formed, showing that all bacteria within the system were killed. Discrepancies between MBC values and the time-kill assays may have arisen from different experimental conditions—the MBC assay involves stationary incubation over 16-18 hours, and the time kill assay is carried out with 90% aeration and rotation over 6 hours.

[0111] To investigate the uptake of 4.sup.4+ by E. coli cells, ICP-AES studies were carried out. Uptake studies with 4.sup.4+ were carried out in the presence and absence of glucose (see FIGS. 1B and 9). Experiments to investigate the accumulation of ruthenium in the E. coli EC958 over an hour were conducted as, at high concentrations, the time kill assays showed 99.9% of bacteria were killed within the first hour of exposure to 4.sup.4+. In these experiments, the concentration of iron, (a trace element in all cells) was also quantified as a control. It was found that on treatment with 4.sup.4+, iron content remained constant; furthermore there was also a negligible change in CFU/mL, demonstrating that cells were not lysed during the accumulation experiment.

[0112] In glucose-free conditions, accumulation shows two phases: after an initial increase on exposure, low levels of ruthenium are maintained for about 20 minutes, after which uptake gradually doubles to a final figure of 1.1×10.sup.−16 g per cell. Assuming an average cell volume of 1 μm.sup.3, this is equivalent to an intracellular concentration of >1 mM. Contrastingly, in the presence of glucose—although the amount of ruthenium that finally accumulates is identical within experimental error—the uptake of the complex is rapid, with the maximum intracellular concentration of ruthenium being reached within 20 minutes. The significant differences between the glucose and glucose-free conditions are seen at 10 and 20 minutes.

[0113] The uptake of 4.sup.4+ and the cellular response to exposure to 4.sup.4+ was also analysed at super resolution using a metal complex. Although structured illumination microscopy was used to image the internalization of 4.sup.4+ at improved resolutions (˜100 nm), we also employed stimulated emission depletion (STED) nanoscopy, to provide the highest sub-diffraction limited resolutions. Example STED images taken over a time-course (5-120 minutes) are shown in FIG. 2.

[0114] To investigate whether changes in cell morphology occur within the first 5-20 minutes of exposure, images were taken at the same time points and identical conditions used in the accumulation experiments. These images confirmed that 4.sup.4+ is readily and rapidly taken up by the pathogenic strain of E. coli. Interestingly, up to 20 minutes, the complex largely accumulates at cellular membranes and is generally distributed within the cell compartment. However, after this period it increasingly preferentially locates at the cell poles.

[0115] STED microscopy was also employed for detailed 3D sectioning experiments (3D STED). By employing a dual STED beam split into the XY plane and Z axis the highest possible 3D resolutions in each imaged plane was facilitated; a critical factor given the cellular dimensions of bacteria. Using this procedure, 3D STED resolutions of 50 nm in each plane and around 120 nm in the Z-axis were obtained. FIG. 3 shows images taken at specific time points after exposure to 4.sup.4+. During the first 10 min the probe accumulates within the cell membrane forming a distinctive distribution pattern. After 20 minutes dye redistribution begins and accumulation at the poles becomes increasingly apparent.

[0116] Taken together with the ICP-AES data the imaging studies indicate a change in the quality of uptake and intracellular distribution of the complex after around 20 minutes. Furthermore, as the molecular weight of 4.sup.4+ is considerably larger than the upper limit for porin-mediated uptake (˜600 Da), this mechanism can be discounted. To investigate the possibility of membrane damage a second co-staining experiment with the probe Alexa Fluor NHS-ester 405 was carried out (see FIG. 4A).

[0117] Since Alexa Fluor NHS-ester 405 is impermeable to non-compromised bacterial membranes it localizes and images cell membranes. Following 5 minutes exposure to 4.sup.4+, localization of NHS-ester 405 is restricted to the cell membrane of bacteria. However, after 60 minutes exposure to the complex, both dyes are found to internalize within E. coli. In contrast, even after 60 minutes, cells solely stained with NHS-ester 405 continue exclusively to display membrane staining. The fact that the membrane stain is internalized only after treatment with 4.sup.4+ offers further evidence that the complex is disrupting the structure of bacterial membranes. To investigate this phenomenon more quantitatively, concentration-dependent ATP cellular leakage assays were performed. Following treatment with specific concentrations of 4.sup.4+, the presence of extracellular ATP, released from damage to bacterial cell membranes, was detected using the luminescence generated from the ATP-dependent reaction between recombinant firefly luciferase and D-luciferin.

[0118] Data obtained from the luminescence-based determination of [ATP], summarized in FIG. 4B, confirm that bacterial membranes are compromised in a concentration-dependent manner on exposure to 4.sup.4+. Given this effect, it seems likely that the uptake of the complex in glucose-free conditions is biphasic, as membrane damage must initially occur before the level of internalized 4.sup.4+ can rise to high concentration. It is possible that this membrane damage is the sole mechanism of therapeutic action for the complex; although—once internalized—the complex localizes and binds at specific regions of the cell suggesting a second cellular target. Given that pathogenic, therapeutically-resistant, strains of E. coli are still sensitive to the complex, it seems likely that the membrane disruption effect of 4.sup.4+ may only be one facet of a more complex set of interactions and cellular responses.

TABLE-US-00002 TABLE 2 UV-Vis spectroscopy data showing the molar extinction coefficient and absorption maxima for the four [{Ru(N—N).sub.2}.sub.2(tpphz)] in water and MeCN. Conducted on a Cary 300 UV/Vis spectrophotometer at 27.5° C. Complex Λmax/nm ε/M.sup.−1 cm.sup.−1 Transition 1.sup.4+ in water 450 34000 MLCT 2.sup.4+ in water insoluble — — 3.sup.4+ in water 454 25300 MLCT 4.sup.4+ in water 430 22833 MLCT 1.sup.4+ in MeCN 450 27000 MLCT 2.sup.4+ in MeCN 450 41000 — 3.sup.4+ in MeCN 449 22700 MLCT 4.sup.4+ in MeCN 432 19498 MLCT

TABLE-US-00003 TABLE 3 Luminescent emission data showing the molar extinction coefficient and absorption maxima for the four [{Ru(N—N).sub.2}.sub.2(tpphz)] in water and MeCN. Conducted on a Fluoromax 3 fluorimeter at 27.5° C. Complex Λmax/nm (MeCN) Λmax/nm (water) 1.sup.4+ 710 — 2.sup.4+ 660 insoluble 3.sup.4+ 670 600 4.sup.4+ 670 650

[0119] As 4.sup.4+ shows high antimicrobial activity and is membrane targeting, the potency of the compound in noncancerous eukaryotic cells was determined to further explore its potential as an antimicrobial theranostic lead. MU-assays on the human embryonic kidney line, HEK293 revealed an average IC.sub.50 value of 135 μM, indicating at least an 80-fold magnitude difference in inhibitory concentration against bacteria and HEK293 cells (see FIG. 4C).

[0120] Given the promising comparison between IC.sub.50 and MIC values, an animal model screen was carried out. As many aspects of the physiology of Galleria mellonella larvae, particularly their immune system, are very similar to mammals they are much employed as an in vivo model, including as a toxicity screen, yielding results that are comparable to commonly used mammalian models. A toxicity screen was conducted with 4.sup.4+ and Kaplan-Meier survival curves plotted (see FIG. 4D). All concentrations used were above the MIC for 4.sup.4+ against EC958, and within the daily dose range used in the clinic for antimicrobials. From Log-rank tests it was determined that there was no significant difference between the percentage survival with the Galleria treated with 4.sup.4+ and the control at all compound concentrations. In addition, activity and melanisation scores showed that there was no significant negative effects on the Galleria exposed to 4.sup.4+, confirming that this compound is not toxic at concentrations well above the MIC.

TABLE-US-00004 TABLE 4 DNA binding constants, and site sizes of four compounds described herein (FIG. 10) Complex I.sub.b/I.sub.f K.sub.b n 1.sup.4+ 60 1.1 × 10.sup.7 2.9 2.sup.4+ 17 5.6 × 10.sup.6 1.26 ± 0.02 3.sup.4+ 27 6.7 × 10.sup.6 1.45 ± 0.02 4.sup.4+ 10 2.4 × 10.sup.6 0.92 ± 0.02

TABLE-US-00005 TABLE 5 log-rank (Mantel-Cox) tests on the Kaplan-Meier survival curves to determine whether a significant difference is observed between the control (water) and compound injected Galleria survival percentages. Galleria were injected with 10 μL of compound (0-80 mg/kg) and stored at 37.5° C. for 120 hours. Concentration/ Chi Survival curve mg kg.sup.−1 square P sig different 1 0.83 0.36 No 5 0.83 0.36 No 10 0.83 0.36 No 20 0.87 0.35 No 40 0.87 0.35 No 80 0.02 0.88 No

[0121] The membrane potentials and flow cytometry behaviour of 4.sup.4+ were determined, as shown in FIGS. 11 and 12. Further, it has been shown that 4.sup.4+ at MIC concentration can penetrate Acetinobacter baumannii (AB184) (FIG. 13). At 10 minutes, the outer membrane can be imaged, at 60, the inner membrane. The localization of 4.sup.4+ in A. baumannii AB184 cells within the larvae's hemolymph is shown in FIG. 17.

[0122] Ruthenium haemolymph content (μg/mL) was determined in Galleria mellonella injected with 4.sup.4+ (FIG. 14). As would be expected, at higher doses, the ruthenium content is higher in the haemolymph, although this remains largely constant over the duration of the experiment. Kaplan Meier infection models (FIG. 15) show good survival at both concentrations of 4.sup.4+ (40 mg/kg and 80 mg/kg) relative to the control (water). Further, FIGS. 16A and 16B show the Bacteria CFU counts from extracted larvae hemolymph (Galleria bacteria). From these plots it is clear that after 48 hours under both treatment concentrations (40 or 80 mg/kg of 4.sup.4+) the colonies were cleared. This clearance was achieved from a single compound dose. In comparison, an exponential increase in bacterial growth was observed in the absence of 4.sup.4+.

[0123] The Galleria mellonella larvae were selected for further study, using the CUBIC clearing protocol. FIG. 18 shows images taken through cleared Galleria wax moth larvae. The luminescence of 4.sup.4+ stained A. baumannii cells at the head (A) and tail (B) of Galleria Mellonella. Regions of A. baumannii cells are highlighted (I,II). Initiation of an immune response in Galleria hemolymph cells is observed (C). The images show the A. baumannii stained with 4.sup.4+ are taken up by the larvae's hemocyte cells and phagocytosed. This indicates that not only does 4.sup.4+ kill the bacteria but it also upregulates the larvae's immune response allowing the infection to be cleared. FIG. 19 also shows images of cleared larvae infected with A. baumannii, AB184, stained with NHS-ester 488 (A) or 4.sup.4+ (B). Sections of the cells are identified (i) and expanded (AII, AIII, BII) to show A. baumannii within the hemocyte cells. 3D surface plots (AIV, BIII) are given to show peak emission intensity.

[0124] In FIG. 20, a study of biofilm formation of E. coli ST131, EC958, when subjected to complex 4.sup.4+ is presented. ST131 formed biofilms in the absence of 4.sup.4+, and at 10% of MIC. Welch's T-test showed no significant difference between these groups (P=0.687). Concentrations of 0.390 and 0.781 showed no biofilm formation having minor negative values of 0.003 and 0.005 respectively. As such, 4.sup.4+ prevents biofilms from forming at concentrations as low at 0.390 μM. FIG. 21 shows a study with pre-formed biolfilms. The biofilms were subjected to 15.6 μM, 78 μM and 156 μM of 4.sup.4+. A one-star significant difference was observed between the control (0 μM) and 156 μM samples (p value=0.0015), and a two-star significant difference was observed between the control (0 μM) and 15.6 μM samples (p value=0.0086). Therefore, 4.sup.4+ has an ability to prevent biofilm formation, and to penetrate existing biofilms.

Synthesis of Mononuclear Complexes

[0125] Complexes 1.sup.2+ and 2.sup.2+ (see scheme 2) were synthesized using the procedures outlined below.

##STR00010##

Ru(N—N).SUB.2.Cl.SUB.2

[0126] Four compounds were synthesised by the following method, where N—N represents the substituted phenanthroline ancillary ligand. RuCl.sub.3.3H.sub.2O, N—N and LiCl were heated in DMF for 8 hours under reflux. The reaction mixture was cooled to room temperature and acetone added. This was stored at 4° C. for 16 hours. The dark purple precipitate was washed with water and ethanol and dried in vacuo.

[Ru(3,4,7,8-tetra methyl-1,10-phenanthroline).SUB.2.Cl.SUB.2.]

[0127] RuCl.sub.3.3H.sub.2O (1.14 g, 5.50 mmol), TMP (2.4 g, 10.16 mmol), LiCl (1.47 g, 34.68 mmol), DMF (19 mL) and acetone (100 mL). Mass=2.07 g (3.21 mmol, 63.2%) purple solid. MS m/z (%): 609.1 (62) [M−Cl].sup.+, 637.1 (100) [M].sup.+ 667.1. (44) [M+Na].sup.+. Carbon monoxide displaced one of the chlorines.

[Ru(N—N).SUB.2.(DPQ)][PF.SUB.6.].SUB.2

[0128] Four compounds were synthesised by the following general procedure. [Ru(N—N).sub.2Cl.sub.2] and DPQ were suspended in a 1:1 solution of EtOH:H.sub.2O. The suspension was refluxed for 12 hours under argon, cooled to room temperature and filtered. NH.sub.4PF.sub.6 was added to form a brown hexafluorophosphate salt.

[Ru(3,4,7,8-tetra methyl-1,10-phenanthroline)(DPQ)][PF.SUB.6.].SUB.2

[0129] [Ru(TMP).sub.2Cl.sub.2] (1.01 g, 1.57 mmol), DPQ (0.495 g, 2.36 mmol) and EtOH:H.sub.2O (50 mL). Mass=0.861 g (0.801 mmol, 51%). MS(TOF MS LD+) m/z (%): 784 (51) [M−2PF.sub.6].sup.2+, 929 (100) [M−PF.sub.6].sup.+. 1 HNMR (DMSO-d.sup.6) δ (splitting integration): 2.23 (6H, s), 2.39 (6H, s), 2.79 (6H, s), 2.85 (6H, s), 7.46 (2H, dd), 7.85 (2H, d), 7.65 (2H, s), 7.95 (2H, s), 8.41 (4H, d), 8.48 (2H, d).

[Ru(N—N).SUB.2.(tpphz)][PF.SUB.6.].SUB.2

[0130] Four compounds were synthesised by the following general procedure. 5,6-diamino-1,10-phenanthroline was dissolved in hot methanol, this was added to a boiling solution of [Ru(N—N).sub.2DPQ][PF.sub.6].sub.2 in acetonitrile. The reaction mixture was heated to reflux at 80° C. for 6 hours. The solution was cooled to room temperature and filtered. NH.sub.4PF.sub.6 was added to form a red hexafluorophosphate salt. The crude product was washed with water, ethanol and diethyl ether. It was then purified on a grade I alumina column with acetonitrile/water/KNO.sub.3. The red band was collected, the solvent removed under reduced pressure and the red solid dried in vacuo.

[Ru(3,4,7,8-tetramethyl-1,10-phenanthroline)(tpphz)][PF.SUB.6.].SUB.2

[0131] 5,6-diamino-1,10-phenanthroline (88.2 mg, 0.42 mmol), hot methanol (17 mL), [Ru(TMP).sub.2DPQ][PF.sub.6].sub.2 (606 mg, 0.56 mmol), acetonitrile (30 mL). Mass=0.272 g (0.389 mmol, 45%), 1 HNMR (CD.sub.3CN-d.sup.6) δ (splitting integration): 2.29 (6H, s), 2.32 (6H, s), 2.80 (6H, s), 2.86 (6H, s), 7.71-7.78 (4H, m), 7.84 (4H, s,), 8.15 (4H, d), 9.30 (4H, d), 9.59 (4H, d). MS; m/z (%): 479 [M−2(PF.sub.6)].sup.2+. Accurate mass analysis: C.sub.56H.sub.44N.sub.10[.sup.102Ru].sup.2+ Calculated 479.1391. Found 479.1405.

Properties of Mononuclear Complexes

[0132] The same parameters and conditions used above to determine MIC and MBC values with respect to compounds 1.sup.4+ to 4.sup.4+ were employed in order to test the MIC and MBC values of complexes 1.sup.2+ to 4.sup.2+.

TABLE-US-00006 TABLE 6 MIC results in for mononuclear complexes MG1655 EC958 V583 SH1000 PA2017 AB184 Complex Defined Medium Values 1.sup.2+ 17.5 34.9 69.8 69.8 34.9 17.5 2.sup.2+ 33.9 33.9 135.6 33.9 16.9 16.4 3.sup.2+ 8.2 16.5 35.8 32.9 16.4 8.5 4.sup.2+ 3.9 3.9 31.1 7.8 7.8 3.6 ampicillin 5 — 7.5 5 — —

TABLE-US-00007 TABLE 7 MBC results in for mononuclear complexes MG1655 EC958 V583 SH1000 PA2017 AB184 Complex Defined Medium Values 1.sup.2+ 34.9 17.5 279.5 69.8 34.9 34.9 2.sup.2+ 33.9 17 271.2 33.9 16.9 16.9 3.sup.2+ 8.2 16.5 131.7 32.9 32.9 8.2 4.sup.2+ 3.9 3.9 31.1 7.8 7.8 3.6 ampicillin 10 — 7.5 10 — —

[0133] As can be seen from Tables 6 and 7, antimicrobial activity was determined from each of compound 1.sup.2+ to 4.sup.2+. Moreover, compound 4.sup.2+ was found to show surprising efficacy as an antibiotic, with better properties than existing antibiotics such as ampicillin. For the avoidance of doubt; SH1000 is Staphylococcus aureus; AB184 is acetinobacter baumanii; and PA2017 is pseudomonas auriginosa.

[0134] Having established that complex 4.sup.2+ had the most promising bactericidal properties, DNA binding (FIG. 22) and time-kill kinetics assays were carried out for E. coli during exposure to increasing concentrations of the complex in minimal media at 37° C. (see FIG. 23). In the presence of glucose, efflux mechanism is observed, clearly indicating that the complex can be actively transported in and out of the cell. FIG. 24 shows the difference in Ru content per cell (g) at the time intervals for FIG. 23, the Ru content is generally higher in the presence of glucose at 5, 10 and 20 minutes, with significant differences observed after 10 minutes.

[0135] E. coli cells treated with 4.sup.2+ at MIC concentration at 1, 2 and 24 hours have shown the onset of multi-nucleated cell filamentation when 4.sup.2+ is present (FIGS. 26 A-C and FIG. 27). This indicates that cell death is caused by DNA damage in the presence of this complex. In FIG. 27, a direct overlay of DAPI and 4.sup.2+ gives a Pearson's colocalisation constant of >0.9. This constant indicates a strong colocalisation confirming 4.sup.2+ targets S. aureus DNA. To corroborate the observations in FIGS. 26 and 27, the mutagenic properties of 4.sup.2+ on E. coli were determined using an Ames mutagenic assay (FIG. 28), as compared to natural mutagenesis and UV-irradiation. At and above the MIC levels of 4.sup.2+ significant DNA mutagenesis is observed, at twice the MIC this is close to the levels observed for UV Irradiation, indicating that 4.sup.2+ causes damage to bacterial cell DNA, as observed in the filamentation shown in FIG. 26. FIG. 29 shows TEM images of E. Coli after treatment with 4.sup.2+, the cell membrane remains intact, providing further evidence that cell death occurs through membrane damage and not membrane lysis. However, there are indications of plasmolysis in the dead cells (for instance the internal cell leakage observed in III), indicating that 4.sup.2+ may also cause osmotic damage to the cells. The DNA damage model is further corroborated by the membrane damage assay of FIG. 30. This assay quantifies extracellular ATP after treatment with different concentrations of 4.sup.2+, relative to the polymyxin control, cells treated with 4.sup.2+ retain ATP. This is believed to be due to the need for extra levels of ATP within the cells to repair damaged DNA.

[0136] Toxicity screening, for 4.sup.2+ (FIG. 31), was completed as described above for 4.sup.4+ (FIG. 4D). 4.sup.2+ is non-toxic to Galleria mellonella up to 80 mg/kg (the maximum clinical daily dose for an antibiotic). As with 4.sup.4+, Mantel-cox Log-rank tests showed there was no statistical difference, at any concentration, between percentage survival for the controls and the compound treated larvae. FIG. 32 provides further toxicity screening data, this time with A. baumannii AB184, in these tests it is clear that the presence of 4.sup.2+ clears the colonies, as all treated larvae survive for the 120 hour duration of the experiment, whereas the larvae not treated with 4.sup.2+ do not survive. Mantel-cox Log-rank studies showed a one-star significant difference in the percentage survival between untreated infected and treated larvae. Further, FIGS. 33A and 33B show the Bacteria CFU counts from extracted larvae hemolymph (A. baumannii AB184 bacteria). From these plots it is clear that after 48 hours under both treatment concentrations (40 or 80 mg/kg of 4.sup.2+) the colonies were cleared. This clearance was achieved from a single compound dose. In comparison, an exponential increase in bacterial growth was observed in the absence of 4.sup.2+.

Comparison of Properties of Mono- and Di-Nuclear Complexes

[0137] To further consider the antimicrobial activity of the compounds 1.sup.4+ to 4.sup.4+ and compounds 1.sup.2+ to 4.sup.2+, compounds 4.sup.4+ and 4.sup.2+ were selected for study with a wide variety of microbes, the results are shown in Table 8 below. The MIC and MBC values were determined as above.

TABLE-US-00008 TABLE 8 MIC and MBC results in for dinuclear and mononuclear complexes Information and Infection Bacteria Strain caused 4.sup.4+ 4.sup.2+ PLANKTONIC ACTIVITY PROFILE (μM) MIC MBC MIC MBC K. NCTC Wild-type non pathogenic 4.8 9.6 31.6 31.6 pneumoniae 13368 K. M6 Carbapenem resistant 4.8 4.8 16 16 pneumoniae Pneumonia, Septicaemia, Meningitis A. baumannii AYE Clinical isolate, multi- 2.4 4.8 31.6 31.6 drug resistant UTI, Catheter bacteremia, Nosocomial infections A. baumannii ATCC Wild-type non pathogenic 1.2 2.4 7.9 7.9 17978 A. baumannii AB12 Clinical isolate, multi- 1.0 1.2 3.9 3.9 drug resistant UTI, Catheter bacteremia, Nosocomial infections A. baumannii AB16 Clinical isolate, multi- 1.67 2.4 10.4 10.4 drug resistant UTI, Catheter bacteremia, Nosocomial infections A. baumannii AB184 Clinical isolate, multi- 1 1.6 3.6 3.6 drug resistant UTI, Catheter bacteremia, Nosocomial infections A. baumannii AB210 Clinical isolate, multi- 0.83 0.8 5.8 10.4 drug resistant UTI, Catheter bacteremia, Nosocomial infections P. PA01 Wild-type non pathogenic 4.8 4.8 15.6 15.6 aureginosa P. PA017 Opportunistic pan-drug 2.4 4.0 15.6 15.6 aureginosa resistant Clinical isolate Lung infections, Septicaemia, Nosocomial infections P. NCTC Multi-drug resistant 4.8 9.6 31.6 31.6 aureginosa 13437 VEB type extended b- lactamase producer Lung infection, Septicaemia, Nosocomial infections P. PA_007_ Carbapenem resistant 4.8 9.6 63.1 63.1 aureginosa IMP IMP (metallo-b-lactamase producing) Lung infection, Septicaemia, Nosocomial infections P. PA_004_ Carbapenem and 4.8 9.6 31.6 31.6 aureginosa CRCN cephalosporin resistant Clinical isolate Lung infection, Septicaemia, Nosocomial infections E. coli NCTC Wild-type non pathogenic 2.4 4.8 7.9 7.9 12923 E. coli PA_007_ Carbapenem resistant 2.4 4.8 3.9 3.9 IMP IMP (metallo-b-lactamase producing) Pneumonia, Septicaemia, UTI E. coli EC958 Multi-drug resistant 1.6 2.4 3.9 3.9 extended b-lactamase producer UTI, Septicaemia, Nosocomial Infections E. coli MG1655 Wild-type non pathogenic 1.2 2.4 3.9 3.9 E. coli APEC Multi-drug resistant 1.6 4.0 1.8 3.9 avian pathogen Septicaemia, Polyserositis, Aerosacculitis B. H111 Opportunistic, multi-drug 2.4 4.0 15.6 15.6 cenocepacia resistant Lung infections, Nosocomial infections E. faecalis V583 Vancomycin resistant 0.5 4.0 31.1 31.1 UTI, GI tract infections, Nosocomial infections S. aureus SH1000 Wild-type non pathogenic 4.0 13.3 7.8 7.8 S. aureus BH1CC Methicillin resistant 38.2 38.2 11.7 11.7 Skin infections, Nosocomial infection S. aureus Clinical Methicillin resistant 19.1 38.2 7.8 7.8 isolate Skin infections, nosocomial infections

[0138] As can be seen, the claimed complexes exhibit activity against a broad library of bacterial strains. In particular, both complexes exhibit high activity across all bacteria, including Carbapenem resistant strains identified by WHO as Priority 1:critical.

[0139] Tables 9 to 11 further compare the activity of complexes 4.sup.4+ and 4.sup.2+ to the clinical standards Gentamicin and Cisplatin.

TABLE-US-00009 TABLE 9 Biofilm activity profile results in for dinuclear and mononuclear complexes against Gram-negative biofilms 44+ 42+ Gentamicin Biofilm Activity Profile (uM) Bacteria Minimum Biofilm Eradication Concentration (MBEC) K. pneumonia 4 32 18 A. baumannii 2 16 9 P. aeruginosa 8 32 18

[0140] As can be seen, both compounds are active on the Gram-negative biofilms tested—indicting that the penetrate and disrupt the biofilms. There is a higher activity with the dinuclear complex, 4.sup.4+, than either 4.sup.2+ or the clinical standard antibiotic gentamicin.

TABLE-US-00010 TABLE 10 Mutation Assay results for dinuclear and mononuclear complexes HPRT forward mutation assay Relative Mutation Condition Mutations Frequency Untreated  7.4 per 1 × 10.sup.5 viable cells 1.0 4.sup.4+ 29.2 per 1 × 10.sup.5 viable cells 1.8 4.sup.2+ 13.2 per 1 × 10.sup.5 viable cells 2.1 Cisplatin 65.5 per 1 × 10.sup.5 viable cells 10.4

[0141] Table 10 shows that at concentrations above the compounds MIC's the complexes were found to exhibit mutagenic frequencies in the range of the untreated control (natural mutagenesis). The mutagenic frequency was lower than that observed with Cisplatin. It is therefore confirmed that the compounds are non-mutagenic to mammalian DNA.

TABLE-US-00011 TABLE 11 Mammalian Cell Toxicity results for dinuclear and mononuclear complexes Mammalian cell toxicity Condition HEK293 MCR5 4.sup.4+ 135 60 4.sup.2+ 23 23 Cisplatin 6 6

[0142] The mammalian cell toxicity data of Table 11, shows that both compounds are less toxic than Cisplatin with the dinuclear 4.sup.4+ being over 10-fold less toxic to healthy eukaryotic cells than this well known drug. In addition, an average therapeutic index of >60 is observed for 4.sup.4+ and ˜6 for 4.sup.2+. In comparison cisplatin has a therapeutic index of 2.

[0143] The relative rates of uptake for complex 4.sup.2+ and 4.sup.4+. Are shown in FIG. 25, an increase in initial rate of uptake was observed relative to complex 4.sup.4+, this is believed to be due to the lower molecular weight of the mononuclear complex.

[0144] Table 12 illustrates the kinetic solubility of complexes 4.sup.2+ and 4.sup.4+ were tested and compared to a soluble positive control drug (Nicardipine). Both compounds passed the DMPK analysis with an optimal solubility and kinetic stability.

TABLE-US-00012 TABLE 12 DMPK Kinetic Turbidimetric Solubility Nominal Concentration Solubility Compound μM Pass/fail Buffer LogS μM 4.sup.2+ 200 Pass pH 7.4 0.8281 6.7 4.sup.2+ 200 Pass pH 7.4 0.7961 6.3 4.sup.4+ 200 Pass pH 7.4 1.138 13.7 4.sup.4+ 200 Pass pH 7.4 1.138 13.7 Nicardipine 200 Pass pH 7.4 1.319 20.8 Nicardipine 200 Pass pH 7.4 1.319 20.8 Nicardipine 200 Pass pH 7.4 1.319 20.8